Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 5/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.51 |
| ▸ | NPC1 | O15118 | 5/20 | 0.51 |
| ▸ | RAB9A | P51151 | 5/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.50 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL301469 | 0.79 | HPGDS (0.71) | HPGDSALDH1A1HSD17B10NPC1RAB9A | |
| SCHEMBL28753616 | 0.77 | HPGDS (0.69) | HPGDSALDH1A1HSD17B10NPC1RAB9A | |
| SCHEMBL3964365 | 0.77 | HPGDS (0.58) | HPGDSLTA4H | |
| SCHEMBL13737200 | 0.77 | HPGDS (0.53) | HPGDSCYP2A6LTA4H | |
| SCHEMBL722557 | 0.75 | LTA4H (0.64) | HPGDSLTA4H | |
| SCHEMBL5571760 | 0.75 | LTA4H (0.70) | HPGDSALDH1A1HSD17B10NPC1RAB9A | |
| SCHEMBL14181278 | 0.74 | HPGDS (0.51) | HPGDSNPC1RAB9ALTA4HPKM | |
| SCHEMBL3222694 | 0.74 | LTA4H (0.53) | HPGDSALDH1A1CYP1A2CYP3A4HSD17B10 | |
| SCHEMBL12571342 | 0.73 | HPGDS (0.50) | HPGDSLTA4H | |
| SCHEMBL16159319 | 0.73 | HPGDS (0.55) | HPGDSLTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115515948-A | PHD inhibitor compounds, compositions and uses | 阿克比治疗有限公司 | 2022-12-23 | — | — | CN | disclosed |
| WO-2020252151-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| EP-3319955-B1 | 6-AMINO-QUINOLINE-3-CARBONITRILS AS COT MODULATORS | GILEAD SCIENCES INC (US) | 2020-11-25 | — | — | EP | disclosed |
| US-10385050-B2 | Indolin-2-one and 1,3-dihydro-pyrrolo[3,2-c]pyridin-2-one derivatives | HOFFMANN-LA ROCHE INC. (US) | 2019-08-20 | — | — | US | disclosed |
| EP-3145923-B1 | INDOLIN-2-ONE AND 1,3-DIHYDRO-PYRROLO[3,2-C]PYRIDIN-2-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2019-01-30 | — | — | EP | disclosed |
| US-20190016719-A1 | INDOLIN-2-ONE AND 1,3-DIHYDRO-PYRROLO[3,2-c]PYRIDIN-2-ONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-10112938-B2 | Indolin-2-one and 1,3-dihydro-pyrrolo[3,2-c]pyridin-2-one derivatives | HOFFMAN-LA ROCHE INC. (US) | 2018-10-30 | — | — | US | disclosed |
| US-9963452-B2 | Methods, compounds, and compositions for inhibition of ROS | AUGUSTA PHARMACEUTICALS INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-20180050997-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2018-02-22 | — | — | US | disclosed |
| CN-107108534-A | Probes for Imaging Huntingtin | CHDI基金会股份有限公司 | 2017-08-29 | — | — | CN | disclosed |
| WO-2008029370-A1 | PYRIDIN-3-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-03-13 | — | — | WO | disclosed |
| US-20040209924-A1 | Substituted 3-pyridyl imidazoles as c17,20 lyase inhibitors | BAYER PHARMACEUTICALS CORPORATION | 2004-10-21 | — | — | US | disclosed |
| US-20040198773-A1 | Substituted 3-pyridyl oxazoles as c17,20 lyase inhibitors | BAYER PHARMACEUTICALS CORPORATION | 2004-10-07 | — | — | US | disclosed |
| US-20040198773-A1 | Substituted 3-pyridyl oxazoles as c17,20 lyase inhibitors | BAYER PHARMACEUTICALS CORPORATION | 2004-10-07 | — | — | US | disclosed |
| US-20040198773-A1 | Substituted 3-pyridyl oxazoles as c17,20 lyase inhibitors | BAYER PHARMACEUTICALS CORPORATION | 2004-10-07 | — | — | US | disclosed |
| WO-2003027107-A1 | SUBSTITUTED 3-PYRIDYL OXAZOLES AS C17,20 LYASE INHIBITORS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
| WO-2003027107-A1 | SUBSTITUTED 3-PYRIDYL OXAZOLES AS C17,20 LYASE INHIBITORS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
| WO-2003027096-A1 | SUBSTITUTED 3-PYRIDYL IMIDAZOLES AS C17,20 LYASE INHIBITORS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
| US-5053416-A | Alzheimer's disease; central cholinomimetic activity | ROUSSEL UCLAF (FR) | 1991-10-01 | — | — | US | disclosed |
| EP-0376848-A1 | Thiazolyl or oxazolyl substituted 1,2,5,6-tetrahydropyridine derivatives, process and intermediates for their preparation, their use as medicaments and compositions containing them | ROUSSEL-UCLAF (FR) | 1990-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10385050-B2 | Indolin-2-one and 1,3-dihydro-pyrrolo[3,2-c]pyridin-2-one derivatives | TPH1, TPH2, HTR1A | HPGDS 1472/4885ALDH1A1 437/4885CYP2A6 625/4885 |
| US-20180050997-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FASN, FABP1, SCD | HPGDS 1097/4885ALDH1A1 1643/4885CYP2A6 594/4885 |
| US-20190016719-A1 | INDOLIN-2-ONE AND 1,3-DIHYDRO-PYRROLO[3,2-c]PYRIDIN-2-ONE DERIVATIVES | TPH1, TPH2, HTR1A | HPGDS 1472/4885ALDH1A1 437/4885CYP2A6 625/4885 |
| US-10112938-B2 | Indolin-2-one and 1,3-dihydro-pyrrolo[3,2-c]pyridin-2-one derivatives | TPH1, TPH2, HTR1A | HPGDS 1472/4885ALDH1A1 437/4885CYP2A6 625/4885 |
| US-20040198773-A1 | Substituted 3-pyridyl oxazoles as c17,20 lyase inhibitors | CYP17A1, HSD17B12, DCLRE1B | HPGDS 1321/4885ALDH1A1 366/4885CYP2A6 3063/4885 |
| US-20040209924-A1 | Substituted 3-pyridyl imidazoles as c17,20 lyase inhibitors | CDC20, IDH1, ALDH18A1 | HPGDS 799/4885ALDH1A1 138/4885CYP2A6 1498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.